Echo Iq's Deal with Pro Medicus Has 3 Big Benefits

Dow Jones06-26 06:30

2230 GMT - Ord Minnett is delighted with Echo IQ's heads of agreement with Pro Medicus to establish the framework for a strategic investment and U.S. commercial partnership. Pro Medicus will invest an initial A$10 million. This will be followed by another A$10 million if Echo IQ's EchoSolv product gets approval by the Food and Drug Administration. "We view the key benefits of the deal as three-fold," says analyst Tom Godfrey. It is a material endorsement and a validation datapoint from a global imaging tech leader in Pro Medicus. It also gives a timely boost to Echo IQ's cash position and leads to a step-change in its immediate U.S. commercialization opportunity. Ord Minnett raises its price target on Echo IQ by 20%, to A$1.80/share. Echo IQ ended Thursday at A$1.615. (david.winning@wsj.com; @dwinningWSJ)

(END) Dow Jones Newswires

June 25, 2026 18:30 ET (22:30 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2646288381?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-26 06:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2646288381","market":"fut","top_or_hot":-1,"title":"Echo Iq's Deal with Pro Medicus Has 3 Big Benefits","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  2230 GMT - Ord Minnett is delighted with Echo IQ's heads of agreement with <a href=\"https://laohu8.com/S/PMCUF\">Pro Medicus</a> to establish the framework for a strategic investment and U.S. commercial partnership. <a href=\"https://laohu8.com/S/PMDIY\">Pro Medicus</a> will invest an initial A$10 million. This will be followed by another A$10 million if Echo IQ's EchoSolv product gets approval by the Food and Drug Administration. \"We view the key benefits of the deal as three-fold,\" says analyst Tom Godfrey. It is a material endorsement and a validation datapoint from a global imaging tech leader in <a href=\"https://laohu8.com/S/PME.AU\">Pro Medicus</a>. It also gives a timely boost to Echo IQ's cash position and leads to a step-change in its immediate U.S. commercialization opportunity. Ord Minnett raises its price target on Echo IQ by 20%, to A$1.80/share. Echo IQ ended Thursday at A$1.615. (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 25, 2026 18:30 ET (22:30 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Echo Iq's Deal with Pro Medicus Has 3 Big Benefits</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEcho Iq's Deal with Pro Medicus Has 3 Big Benefits\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-26 06:30</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  2230 GMT - Ord Minnett is delighted with Echo IQ's heads of agreement with <a href=\"https://laohu8.com/S/PMCUF\">Pro Medicus</a> to establish the framework for a strategic investment and U.S. commercial partnership. <a href=\"https://laohu8.com/S/PMDIY\">Pro Medicus</a> will invest an initial A$10 million. This will be followed by another A$10 million if Echo IQ's EchoSolv product gets approval by the Food and Drug Administration. \"We view the key benefits of the deal as three-fold,\" says analyst Tom Godfrey. It is a material endorsement and a validation datapoint from a global imaging tech leader in <a href=\"https://laohu8.com/S/PME.AU\">Pro Medicus</a>. It also gives a timely boost to Echo IQ's cash position and leads to a step-change in its immediate U.S. commercialization opportunity. Ord Minnett raises its price target on Echo IQ by 20%, to A$1.80/share. Echo IQ ended Thursday at A$1.615. (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 25, 2026 18:30 ET (22:30 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4531","symbol_name":"中概回港概念","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2646288381","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2646288381","pubTimestamp":1782426600,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"2230 GMT - Ord Minnett is delighted with Echo IQ's heads of agreement with Pro Medicus to establish the framework for a strategic investment and U.S. commercial partnership. Pro Medicus will invest an initial A$10 million. This will be followed by another A$10 million if Echo IQ's EchoSolv product gets approval by the Food and Drug Administration. \"We view the key benefits of the deal as three-fold,\" says analyst Tom Godfrey. It is a material endorsement and a validation datapoint from a global imaging tech leader in Pro Medicus. It also gives a timely boost to Echo IQ's cash position and leads to a step-change in its immediate U.S. commercialization opportunity. Ord Minnett raises its price target on Echo IQ by 20%, to A$1.80/share. Echo IQ ended Thursday at A$1.615.  Dow Jones NewswiresJune 25, 2026 18:30 ET Copyright  2026 Dow Jones & Company, Inc.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4531":"中概回港概念","BK7016":"应用软件","IQ":"爱奇艺","BK4108":"电影和娱乐","BK4526":"热门中概股","BK4505":"高瓴资本持仓","BK4552":"Archegos爆仓风波概念","EIQ.AU":"ECHOIQ LTD"},"translate_title":"Echo Iq与Pro Medicus的交易有3大好处","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IQ":0.87,"EIQ.AU":0.9},"content_text":"2230 GMT - Ord Minnett is delighted with Echo IQ's heads of agreement with Pro Medicus to establish the framework for a strategic investment and U.S. commercial partnership. Pro Medicus will invest an initial A$10 million. This will be followed by another A$10 million if Echo IQ's EchoSolv product gets approval by the Food and Drug Administration. \"We view the key benefits of the deal as three-fold,\" says analyst Tom Godfrey. It is a material endorsement and a validation datapoint from a global imaging tech leader in Pro Medicus. It also gives a timely boost to Echo IQ's cash position and leads to a step-change in its immediate U.S. commercialization opportunity. Ord Minnett raises its price target on Echo IQ by 20%, to A$1.80/share. Echo IQ ended Thursday at A$1.615. (david.winning@wsj.com; @dwinningWSJ) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 25, 2026 18:30 ET (22:30 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2646288381","isCrawlerRequest":true}